Skip to main content

Notice for dasatinib (Bristol-Myers Squibb Australia Pty Ltd)

Active ingredients
dasatinib
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Tablet, film-coated
Indication
For the treatment of paediatric patients with chronic myeloid leukaemia
Therapeutic area
Haematology

Help us improve the Therapeutic Goods Administration site